STAT

At Silicon Valley’s debutante ball for startups, there’s more biology than ever

More than ever before, startups at this storied pitch fest are touting ideas for the life sciences — and that has biology and tech colliding in surprising ways. Like a…

MOUNTAIN VIEW, Calif. — Clad in T-shirts, the startup founders cycled through the stage, each whizzing through a two-minute pitch packed with wildly optimistic promises and generously large market estimates.

Some pitched the usual Silicon Valley fare, like drones and live-streamed fitness classes and aimed at hip millennials. But more than ever before, many of them pitched ideas for the life sciences: for synthetic biology. An experimental cell therapy for patients with liver disease. And a that aims to bypass needles altogether by collecting blood from women’s used menstrual pads — and in doing so collect reams of data that

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Moderna Covid-flu Vaccine, A Paused Pfizer Study, And More
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 trial than individual vaccines.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo’s Wegovy Approval In China, A Merck KGaA Cancer Trial Failure, And More
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people.
STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.

Related Books & Audiobooks